US govt seeks new trial in Gilead HIV drug patent case
18-05-2023
Gilead defeats US govt in billion-dollar HIV drug patent suit
11-05-2023
Sundry Photography / Shutterstock.com
Verdict confirms legality of 2014 patent settlement, dismissing allegations of anti competitive practices.
Gilead Sciences and Teva Pharmaceuticals Industries have received a favourable verdict in an HIV antitrust trial in the US District Court for the Northern District of California.
The lawsuit, brought by consumers and direct purchasers, including the Blue Cross and Blue Shield Association, accused Gilead of maintaining a monopoly in the HIV drug market by unlawfully extending patent protection to delay generic competition.
The plaintiffs sought $3.6 billion in damages.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Gilead Sciences, Teva Pharmaceuticals Industries, HIV, antitrust, US District Court, Deborah Telman, US
